Oppenheimer Downgrades Bio-Reference Laboratories (BRLI) to Perform
More News related to BRLI
- Bio-Reference Laboratories, Inc. Again Awarded New York State Department of Corrections Laboratory Services Contract
- SmallCapSentinel.com: Records and Revenues
- BioReference Laboratories, Inc to Speak at the Oppenheimer 20th Annual Health Care Conference
- Bio-Reference Laboratories (BRLI) Tops The Q3 View By 8c
- Jefferies & Co Downgrades Bio-Reference Labs (BRLI) to Hold
More News related to Downgrades
- JANCO Partners Downgrades Energy Conversion Devices (ENER) to Sell
- Feltl & Co. Downgrades ArcSight (ARST) to Sell
- Credit Suisse Downgrades Comcast (CMCSA) to Neutral
- Citi Downgrades AK Steel (AKS) to Hold
- Citi Downgrades Netflix (NFLX) to Hold
Oppenheimer downgrades Bio-Reference Laboratories (Nasdaq: BRLI) from Outperform to Perform. Price target $25.
Bio-Reference Laboratories, Inc. is an independent regional clinical laboratory servicing the greater New York metropolitan area.
Related Categories
DowngradesStocks Mentioned
+0.88Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
